Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

VKTX

Viking Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1607678Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$0.0M
Net Income FY2025
$(360.0M)
EPS (Basic, as reported)
$-3.19
Net Margin FY2025
—
ROE FY2025
-56.3%
Total Equity
$639.0M
Shares Out
128M
Business description

Viking Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2014–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 0
Revenue0000000000
Research & development(9)(14)(19)(24)(32)(45)(54)(64)(102)(345)
General & administrative(5)(5)(7)(9)(11)(11)(16)(37)(49)(48)
Total operating expenses(14)(19)(26)(33)(43)(56)(70)(101)(151)(393)
Operating income(14)(19)(26)(33)(43)(56)(70)(101)(151)(393)
Other income (expense), net(1)(2)47311154134
Pre-tax income———————(86)(110)(360)
Income tax expense0000000000
Net income(15)(21)(22)(26)(39)(55)(69)(86)(110)(360)
EPS — basic—————($0.71)($0.90)($0.91)($1.01)($3.19)
EPS — diluted—————($0.71)($0.90)($0.91)($1.01)($3.19)
Shares outstanding — basic (M)—————777794109113
Shares outstanding — diluted (M)—————777794109113

Showing the latest 10 of 12 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.